Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.

Overview of attention for article published in Clinical Cancer Research, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

So far, Altmetric has seen 28 X posts from 19 X users, with an upper bound of 61,067 followers.

RT @BrainTumorInst: Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in #BreastCancer and #G…

Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in #BreastCancer and #Glioblastoma: https://t.co/BEYxNreakN. @adam_sonabend @maciejlesniakmd @VictorA_Arrieta @CatyLeechang @LurieCancer

RT @BrainTumorInst: Can a commonly utilized breast cancer treatment cross the blood-brain barrier? A team led by @adam_sonabend discovered…

RT @BrainTumorInst: Can a commonly utilized breast cancer treatment cross the blood-brain barrier? A team led by @adam_sonabend discovered…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 24 additional X posts.